1st Counsel – Lifestyle
Author:
Rezolute, Inc.
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
May 12, 2026
Rezolute to Participate in Upcoming Investor Conferences
May 11, 2026
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
May 1, 2026
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
April 21, 2026
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
March 24, 2026